MedPath

A 'Non-Invasive' Breath Test to Determine Anabolic Sensitivity in Females

Not Applicable
Recruiting
Conditions
Dietary Protein
Young Adult Females
Female Protein Metabolism
Resistance Exercise
Anabolic Sensitivity
Interventions
Behavioral: Fed
Behavioral: Ex-Fed
Registration Number
NCT05422300
Lead Sponsor
University of Toronto
Brief Summary

The maintenance of lean body mass, especially skeletal muscle, is vital for optimal health and performance across the lifespan. The protein component of lean body mass is in a constant state of turnover, involving the simultaneous breakdown of old and/or damaged proteins and the synthesis of new proteins. These processes collectively determine if someone gains or loses lean body mass. Eating a protein-rich meal or performing resistance exercise can stimulate protein synthesis to gain lean body mass. Stable isotope "tracers" are amino acid building blocks that are slightly heavier than those naturally found in the body. In research, these are often used to assess changes in protein turnover in response to feeding and/or exercise. However, traditional stable isotope tracer methods involve the intravenous delivery of a tracer with blood sampling and muscle biopsies, which may be cumbersome or unfeasible for some for participants.

The investigators have recently developed and validated a non-invasive 'breath test' in males that measures the efficiency of the body for using amino acids in food to build new body proteins. The principle of this method is that leucine, an essential amino acid that the body must acquire from normal diet, can be used to build new body proteins or as a source of energy (i.e., oxidized). Since leucine is preferentially used in skeletal muscle, skeletal muscle protein metabolism can be non-invasively inferred . Any leucine "tracer" that is oxidized can be detected and measured in the carbon dioxide exhaled. It has been observed that less dietary leucine is oxidized when active males perform a bout of resistance exercise, meaning more was used to build muscle proteins. When performed habitually, resistance exercise can help skeletal muscles grow, compared to a rested-state, resulting in greater leucine retention in the body to build new proteins. Therefore, the purpose of this study is to validate this non-invasive breath test in females to increase the validity of the method in a wider range of populations. Ultimately, the results will further validate this non-invasive tool that can potentially detect whether different populations are sensitive to dietary amino acids and in a position to gain or lose lean body mass.

Detailed Description

The objective of the present study is to validate the use of an oral L-\[13C\]-leucine stable isotope tracer, preferentially metabolized within skeletal muscle, to detect an exercise-induced increase in anabolic sensitivity (i.e., reduction in oxidation) in females. It is hypothesized that since resistance exercise enhances skeletal muscle protein synthesis, anabolic sensitivity measured through leucine retention would be greater with feeding after resistance exercise compared to feeding at rest.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
10
Inclusion Criteria
  • Female sex
  • 18-35 years of age
  • BMI ≥18.5 kg/m2 and ≤ 30 kg/m2
  • Eumenorrheic (self-reported menstruation for prior 3 consecutive months)
  • Recreationally active; currently performing structured exercise (e.g. running, weightlifting, team-sport activity) at least once per week for ≥ 6 months before enrolment
Exclusion Criteria
  • Use of oral contraceptives
  • Inability to perform physical activity as determined by the PAR-Q+
  • Inability to adhere to protocol guidelines (e.g. alcohol, caffeine, habitual diet)
  • Regular tobacco use
  • Illicit drug use (e.g. growth hormone, testosterone, etc...)
  • Diagnosed medical condition under the care of a physician (e.g. type 2 diabetes)
  • Inability to abstain from supplements (e.g. protein, creatine, HMB, BCAA, phosphatidic acid, etc...) at least three weeks before the trial
  • Individuals on any medications known to affect protein metabolism (e.g. corticosteroids, non-steroidal anti-inflammatories, and/or prescription-strength acne medications)

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Mid-Follicular PhaseEx-Fed7-10 days after the onset of menses, determined by self-reports and confirmed with ovulation test kits.
Mid-Luteal PhaseFed5-7 days after ovulation, determined by self-reports and confirmed with ovulation test kits.
Mid-Follicular PhaseFed7-10 days after the onset of menses, determined by self-reports and confirmed with ovulation test kits.
Mid-Luteal PhaseEx-Fed5-7 days after ovulation, determined by self-reports and confirmed with ovulation test kits.
Primary Outcome Measures
NameTimeMethod
Net-Leucine Retention (umol/kg)6 hours

Whole-Body Net Leucine Retention determined from the difference between exogenous leucine oxidation and leucine ingestion the 6 hour measurement period.

Exogenous Leucine Oxidation (umol/kg)6 hours

Exogenous Leucine Oxidation determined from breath 13CCO2 enrichment. Breath samples will be collected every 20-30min after test drink ingestion to determine breath 13CO2 enrichment. Total leucine oxidation will be determined from the area under the 13CO2 enrichment by time curve.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Toronto

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath